Odonate Therapeutics, Inc. Common Stock
ODT was delisted on the 14th of January, 2022.
50 hedge funds and large institutions have $516M invested in Odonate Therapeutics, Inc. Common Stock in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 22 increasing their positions, 10 reducing their positions, and 2 closing their positions.
250% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 2
120% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 10
11% more funds holding
Funds holding: 45 → 50 (+5)
9% more capital invested
Capital invested by funds: $471M → $516M (+$44.7M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$20.7M |
| 2 |
BC
Broadfin Capital
New York
|
+$2.17M |
| 3 |
Bank of New York Mellon
New York
|
+$1.5M |
| 4 |
BlackRock
New York
|
+$1.17M |
| 5 |
AA
ALPS Advisors
Denver,
Colorado
|
+$909K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$3.63M |
| 2 |
Goldman Sachs
New York
|
-$675K |
| 3 |
D.E. Shaw & Co
New York
|
-$359K |
| 4 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$123K |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$98.6K |
ODT Hedge Fund Activity: Q2 2018 in Review
50 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Odonate Therapeutics, Inc. Common Stock (ODT) for Q2 2018, worth a combined $516M — up 9.5% from $471M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ODT positions and 2 closed out — a net gain of 5 holders — while 22 added to existing stakes and 10 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $20.7M. The largest seller was Sabby Management, cutting an estimated $3.63M.
- 50 institutional investors held Odonate Therapeutics, Inc. Common Stock (ODT) as of Q2 2018, up from 45 in Q1 2018.
- Funds reported $516M of Odonate Therapeutics, Inc. Common Stock stock for Q2 2018, up 9.5% quarter-over-quarter.
- 7 funds opened new Odonate Therapeutics, Inc. Common Stock positions in Q2 2018 and 2 closed out, a net change of +5 holders.
- The largest Odonate Therapeutics, Inc. Common Stock buyer in Q2 2018 was Janus Henderson Group, an estimated $20.7M added.
- The largest Odonate Therapeutics, Inc. Common Stock seller in Q2 2018 was Sabby Management, an estimated $3.63M sold.
Based on aggregated 13F filings for Q2 2018.